期刊文献+

非酒精性脂肪肝患者血清非高密度脂蛋白胆固醇水平检测分析 被引量:3

Detection of serum non-high-density lipoprotein cholesterol levels in patients with nonalcoholic fatty liver
下载PDF
导出
摘要 目的了解非酒精性脂肪肝患者血清非高密度脂蛋白胆固醇(non-HDL-C)代谢水平,评价其临床应用价值。方法通过对单位体检者的影像学检查及肝功能、血糖、血脂等血清生化指标检测,并对其中非酒精性脂肪肝与体检健康者(对照组)进行比较。结果脂肪肝总检出率为9.15%,男性检出率12.50%,显著高于女性的5.99%(P〈0.05);男性患者丙氨酸转氨酶(ALT)、间接胆红素(IBil)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白A1(apoA1)、non-HDL-C、apoB100/apoA1、LDL-C/HDL-C、apoB100/HDL-C、总胆固醇/高密度脂蛋白胆固醇(TC/HDL-C)等与对照组比较差异具有统计学意义(P〈0.05或P〈0.01),女性患者天冬氨酸转氨酶(AST)、总胆红素(TBil)、直接胆红素(DBil)I、Bil、葡萄糖(Glu)、TC、TG、LDL-C、apoA1、non-HDL-C、apoB100/apoA1、LDL-C/HDL-C、apoB100/HDL-C、TC/HDL-C与对照组比较差异具有统计学意义(P〈0.05或P〈0.01);non-HDL-C与TC、LDL-C、TG、HDL-C、apoA1、apoB100、apoB100/apoA1、TC/HDL均显著相关(r=0.411~0.989,P〈0.01)。结论非酒精性脂肪肝普遍具有脂类代谢异常和肝脏受损特点,non-HDL-C的检测有助于全面了解非酒精性脂肪肝脂类代谢状况。 Objective To understand the clinical significance of serum non-high-density lipoprotein cholesterol (non-DHL-C) levels in the patients with nonalcoholic fatty liver. Methods The nonalcoholic fatty liver and the health persons(contrast group) physical examination were compared by image analysis and blood serum biochemical indicators about liver function, blood glucose(Glu) and blood fat. Results The detection rate of fatty liver was 9.15 %. The rate of male patients was 12.50 %, which was higher than that of female patients, 5.99 % ( P 〈0.05). There were significant differences in the levels of alanine aminotransferase (ALT), indirect bilirubin (IBiL), triglyeride (TG), high-density lipoprotein cholesterol( HDL-C), low-density lipoprotein cholesterol ( LDL-C), apolipoprotein a (apoA1), non-HDL-C, apoB100/apoA1, LDL-C/HDL-C, apoB100/HDL-C and TC/HDL-C between male patients and contrast group ( P 〈0.05 or P〈0.01), also in the levels of aspartate aminotransferase (AST), total bilirubin(TBiL), direct bilirubin(DBiL), IBiL, Glu, TC, TG, LDL-C, apoA1, non-HDL-C, apoB100/apoA1, LDL-C/HDL-C, apoB100/HDL-C and TC/HDL-C between female patients and contrast group (P〈0.05 or P 〈20.01). Non-HDL-C was obviously associated with TC, LDL-C,TG,HDL-C,apoA1 ,apoB100 ,apoB100/apoA1 and TC/HDL-C ( r =0. 411-0. 989, P 〈0.01). Conclusion The metabolism disorders exist in the patients with nonalcoholic fatty liver. Early detection of serum non-HDL-C levels may be helpful to know the metabolism condition of plasma lipids.
出处 《临床荟萃》 CAS 北大核心 2007年第12期856-859,共4页 Clinical Focus
关键词 脂肪肝 肝功能试验 脂蛋白类 HDL胆固醇 性别分布 强制性体检 fatty liver liver function tests lipoproteins, HDL cholesterol sex distribution madatory tests
  • 相关文献

参考文献2

二级参考文献54

  • 1胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. 被引量:108
  • 2Schwimmer JB,Behling C,Newbury R,et al.Histopathology of pediatric nonalcoholic fatty liver disease.Hepatology,2005,42:641-649.
  • 3Neuschwander Tetri BA,Caldwell SH.Nonalcoholic steatohepatitis:summary of an AASLD Single Topic Conference.Hepatology,2003,37:1202-1219.
  • 4Angulo P.Nonalcoholic fatty liver disease.N Engl J Med,2002,346:1221-1231.
  • 5Ghali P,Lindor KD.Hepatotoxicity of drugs used for treatment of obesity and its comorbidities.Semin Liver Dis,2004,24:389-397.
  • 6Harrison SA,Torgerson S,Hayashi P,et al.Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.Am J Gastroenterol,2003,98:2485-2490.
  • 7Angulo P.Use of ursodeoxycholic acid in patients with liver disease.Curr Gastroenterol Rep,2002,4:37-44.
  • 8Agrawal S,Bonkovsky HL.Management of nonalcoholic steatohepatitis:an analytic review.J Clin Gastroenterol,2002,35:253-261.
  • 9Comar KM,Sterling RK.Drug therapy for non-alcoholic fatty liver disease.Aliment Pharmacal Ther,2006,23:207-215.
  • 10Lok AS,McMahon B J; Practice Guidelines Committee,American Association for the Study of Liver Diseases (AASLD).Chronic hepatitis B:update of recommendations.Hepatology,2004,39:857-861.

共引文献1514

同被引文献28

  • 1中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].中国肝脏病杂志(电子版),2010,2(4):43-48. 被引量:472
  • 2黄正明,贾万年.脂肪肝[M】.北京:人民军医出版社,2012:5-11.
  • 3Mili S, Stimac D. Nonalcoholic fatty liver disease/ steatohepatitis : epidemiology, pathogenesis, clinical presentation and treatmentEJ3. Dig Dis,2012,30(2):158-162.
  • 4Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome~ 25-26 August 2002, Washington, DC[J]. Diabetes Care,2003,26(4) : 1297-1303.
  • 5Clark JM,Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies [J]. Gastroenterology, 2003,124(1) :248-250.
  • 6Sanyal AJ, American Gastr0enterological Association. AGA technical review on nonalcoholic fatty liver disease [J]. Gastroenterology, 2002,123 (5) :1705-1725.
  • 7Oh HJ,Kim TH,Sohn YW,et al. Association of serum alanine aminotransferase and γ-glutamyltransferase levels within the reference range with metabolic syndrome and nonalcoholic fatty liver disease[J].Korean J Hepatol, 2011,17 ( 1 ) : 27-36.
  • 8Oh SY, Cho Y.K, Kang MS, et al. The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease [J]. Metabolism, 2006,55(12) : 1604-1609.
  • 9Guzzaloni G, Grugni G, Minocci A, et al. Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test[J]. Int J Obes Relat MetabDisord,2000,24(6):772-776.
  • 10沈琪琳,周位强,苏莉,吕惠娟,姜锋.血清非高密度脂蛋白胆固醇测定在非酒精性脂肪肝中的应用[J].检验医学,2008,23(2):152-155. 被引量:5

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部